Drug · Small Molecule
Ibuprofen
CI-DRUG-00000291Explore in graph →NCIt C561 CHEMBL521 CIViC Approved
Regulatory
Approvals (14)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
openfdaProvenance
- Source
- openFDA — Drugs@FDA applications and drug labels (SPL)
- Dataset
- Drugs@FDA via openFDA
- Version
- drugsfda-2026-09-04
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- CC0 1.0 Universal (public domain; https://open.fda.gov/license/)
- Run
- ING-OPENFDA-20260908-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| US FDA | — | Efficacy supplement 2026-01-23 (see label) | approved | Jan 23, 2026 | openfda |
| US FDA | — | Efficacy supplement 2023-05-11 (see label) | approved | May 11, 2023 | openfda |
| US FDA | — | Efficacy supplement 2021-11-19 (see label) | approved | Nov 19, 2021 | openfda |
| US FDA | — | Efficacy supplement 2015-11-20 (see label) | approved | Nov 20, 2015 | openfda |
| US |
Data updated 2 days agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 2 | 1 | 4 | 20 | 14 | US | Jun 16, 1995 | 2001-02 |
| Malignant Kidney Neoplasm | Phase2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Sep 15, 2023 |
| Malignant Prostate Neoplasm | Phase2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 1, 2018 |
| Hodgkin Lymphoma | Phase1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — |
Curated evidence
Clinical evidence (1)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 30683736
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA Amplification1 | ||||||||
| Aspirin + Ibuprofen | ||||||||
Clinical trials
Trials with this intervention (20)
Most recently updated first, 50 per page.
clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05842044 | NSAID Use After Robotic Partial Nephrectomy(No-PAIN) | recruiting | Phase 2 | 110 | University of MiamiOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07682558 | Efficacy of Non-opioid Drugs in Addition to Opioid Therapy for Cancer Pain Management(NoDoubt) | not yet recruiting |